STOCK TITAN
  1. Home
  2. Sec-filings
  3. KROS
  4. [8-K] Keros Therapeutics, Inc. Reports Material Event

Keros Therapeutics (NASDAQ: KROS) details Q2 2026 results press release

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Keros Therapeutics, Inc. reported that it has issued a press release with its financial results for the quarter ended June 30, 2026. The press release, dated August 3, 2026, is provided as Exhibit 99.1 and is incorporated by reference for those detailed figures and disclosures.

Positive

  • None.

Negative

  • None.

Filing Explained

The June 30, 2026 results release is furnished under Item 2.02, not treated as filed for Exchange Act Section 18 purposes, and not incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Quarter end date June 30, 2026 Period for which financial results were announced
Press release exhibit 99.1 Exhibit containing the detailed quarterly financial results
Results of Operations and Financial Condition financial
"Item 2.02 Results of Operations and Financial Condition."
emerging growth company regulatory
"Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What did Keros Therapeutics (KROS) disclose in the August 3, 2026 report?
Keros Therapeutics disclosed that it issued a press release presenting its financial results for the quarter ended June 30, 2026. The press release, dated August 3, 2026, is furnished as Exhibit 99.1 and contains the detailed financial information.

Which period do the latest Keros Therapeutics (KROS) results cover?
The latest reported results for Keros Therapeutics cover the quarter ended June 30, 2026. These quarterly financial results are summarized in a press release dated August 3, 2026, which is furnished as Exhibit 99.1 for full financial and operational details.

How did Keros Therapeutics (KROS) provide its Q2 2026 financial information?
Keros Therapeutics provided its Q2 2026 financial information through a press release announcing results for the quarter ended June 30, 2026. This press release is dated August 3, 2026 and is made available as Exhibit 99.1 with detailed figures.

Is the Keros Therapeutics (KROS) Q2 2026 press release considered filed with the SEC?
The Q2 2026 press release for Keros Therapeutics is furnished, not filed, for Exchange Act Section 18 purposes. It is included as Exhibit 99.1, limiting the associated liabilities and incorporation into other securities law filings unless specifically referenced.

Where can investors find detailed Q2 2026 numbers for Keros Therapeutics (KROS)?
Detailed Q2 2026 numbers are contained in Keros Therapeutics’ press release dated August 3, 2026. This release, covering the quarter ended June 30, 2026, is furnished as Exhibit 99.1, which holds the specific financial statements and metrics.
0001664710FALSE00016647102026-08-032026-08-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 3, 2026
 
Keros Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware001-3926481-1173868
(state or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
1050 Waltham Street, Suite 302
Lexington, Massachusetts
02421
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (617) 314-6297
 
Not applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
 
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 


 
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading
Symbol
Name of each exchange
on which registered
Common Stock, $0.0001 par value per shareKROSThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 


Item 2.02    Results of Operations and Financial Condition.
 
On August 3, 2026, Keros Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained in this Item 2.02 and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.  
Item 9.01     Financial Statements and Exhibits.
 
(d) Exhibits
Exhibit
No.Description
99.1
Press Release dated August 3, 2026.
104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
KEROS THERAPEUTICS, INC.
By:/s/ Jasbir Seehra
Jasbir Seehra, Ph.D.
Chief Executive Officer
Dated: August 3, 2026

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents